Clinical Dialogue: Use of Biosimilars in the Management of Rheumatologic and Gastrointestinal Diseases

Biosimilars represent new options for the management of patients with rheumatologic and gastrointestinal diseases. The nature of biosimilars and the ways in which they should be used in clinical practice can be confusing to clinicians. An improved understanding of these agents will help to optimize the use of biosimilars.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:
  • Differentiate between biosimilar drugs and generic (bioequivalent) drugs.
  • Identify FDA’s basis for licensure of biosimilars.
  • Identify available biosimilars indicated for rheumatologic and gastrointestinal disorders.
  • Indicate how biosimilars should be used in clinical practice.